SRPT supply chain intelligence for Sarepta Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ROCHE | ROCHE | 90% | if we fail to supply ELEVIDYS to Roche in accordance with the terms of the Roche Agreement and the supply agreements to be entered into between the parties |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 80% | past several years to further enhance our internal research and development capabilities. However, we currently do not have internal GMP manufacturing capabilities to produce our products and product… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 80% | Reciprocal relationship from ARWR graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from SRPT graph: past several years to further enhan… |
| MYONEXUS-THERAPEUTICS-INC | MYONEXUS-THERAPEUTICS-INC | 80% | As part of the consideration for the transaction, we are required to make contingent payments to the former shareholders of Myonexus upon achievement of a threshold amount of net sales of Myonexus products |
| BMRN | BioMarin Pharmaceutical Inc. | 72% | Reciprocal relationship from BMRN graph: Reciprocal relationship from SRPT graph: past several years to further enhance our internal research and development capabilities. However, we currently do no… |
| BMRN | BioMarin Pharmaceutical Inc. | 72% | past several years to further enhance our internal research and development capabilities. However, we currently do not have internal GMP manufacturing capabilities to produce our products and product… |
| CAPR | Capricor Therapeutics, Inc. | 72% | Reciprocal relationship from CAPR graph: be engaged in other clinical trial programs for the same indication as our product candidates or may otherwise be resource constrained. We may be required to … |
| DYN | Dyne Therapeutics, Inc. | 72% | Reciprocal relationship from DYN graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disru… |
| KROS | Keros Therapeutics, Inc. | 72% | Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirement… |
| RGNX | REGENXBIO Inc. | 72% | Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that … |
| TRDA | Entrada Therapeutics, Inc. | 72% | Reciprocal relationship from TRDA graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from TRDA graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from TRDA g… |
| BIOMARIN-LEIDEN-HOLDING-BV | BIOMARIN-LEIDEN-HOLDING-BV | 70% | we executed a license agreement with BioMarin Leiden Holding BV, BioMarin Nederlands BV and BioMarin Technologies BV (collectively, the "BioMarin Parties"), pursuant to which BioMarin Parties granted… |
| BIOMARIN-NEDERLANDS-BV | BIOMARIN-NEDERLANDS-BV | 70% | we executed a license agreement with BioMarin Leiden Holding BV, BioMarin Nederlands BV and BioMarin Technologies BV (collectively, the "BioMarin Parties"), pursuant to which BioMarin Parties granted… |
| BIOMARIN-TECHNOLOGIES-BV | BIOMARIN-TECHNOLOGIES-BV | 70% | we executed a license agreement with BioMarin Leiden Holding BV, BioMarin Nederlands BV and BioMarin Technologies BV (collectively, the "BioMarin Parties"), pursuant to which BioMarin Parties granted… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CUSTOMER-1 | CUSTOMER-1 | 90% | For the Three Months Ended March 31, 2026 2025 Product revenues, net Customer 1 39 % 19 % |
| CUSTOMER-2 | CUSTOMER-2 | 90% | For the Three Months Ended March 31, 2026 2025 Product revenues, net Customer 2 20 % 12 % |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | past several years to further enhance our internal research and development capabilities. However, we currently do not have internal GMP manufacturing capabilities to produce our products and product… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ARWR graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from ARWR g… |
| BMRN | BioMarin Pharmaceutical Inc. | 72% | Reciprocal relationship from BMRN graph: Reciprocal relationship from SRPT graph: past several years to further enhance our internal research and development capabilities. However, we currently do no… |
| BMRN | BioMarin Pharmaceutical Inc. | 72% | past several years to further enhance our internal research and development capabilities. However, we currently do not have internal GMP manufacturing capabilities to produce our products and product… |
| CAPR | Capricor Therapeutics, Inc. | 72% | Reciprocal relationship from CAPR graph: be engaged in other clinical trial programs for the same indication as our product candidates or may otherwise be resource constrained. We may be required to … |
| KROS | Keros Therapeutics, Inc. | 72% | Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirement… |
| RGNX | REGENXBIO Inc. | 72% | Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that … |
| TRDA | Entrada Therapeutics, Inc. | 72% | Reciprocal relationship from TRDA graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from TRDA graph: everal risks, including disruptions in supply, price increases or late deliv… |
| ANNUAL-REPORT-F-HOFFMAN-LA-ROCHE-LTD | ANNUAL-REPORT-F-HOFFMAN-LA-ROCHE-LTD | 62% | rease overall capacity as well as further reduce risks associated with relying on a limited number of suppliers for manufacturing. Our gene therapy manufacturing capabilities have been greatly enhanc… |
| ARROWHEAD-COLLABORATION-AGREEMENT-SAREPTA-THERAP | ARROWHEAD-COLLABORATION-AGREEMENT-SAREPTA-THERAP | 62% | and certain legal actions in Europe (the “Actions”) would be stopped or withdrawn as between the Settlement Parties. Specifically, the terms of the Settlement Agreement required that existing efforts… |
| CATALENT-MARYLAND-INC | CATALENT-MARYLAND-INC | 62% | and certain legal actions in Europe (the “Actions”) would be stopped or withdrawn as between the Settlement Parties. Specifically, the terms of the Settlement Agreement required that existing efforts… |
| MYONEXUS-THERAPEUTICS-INC | MYONEXUS-THERAPEUTICS-INC | 62% | rease overall capacity as well as further reduce risks associated with relying on a limited number of suppliers for manufacturing. Our gene therapy manufacturing capabilities have been greatly enhanc… |
| NATIONWIDE-ARROWHEAD-PHARMACEUTICALS-INC | NATIONWIDE-ARROWHEAD-PHARMACEUTICALS-INC | 62% | and certain legal actions in Europe (the “Actions”) would be stopped or withdrawn as between the Settlement Parties. Specifically, the terms of the Settlement Agreement required that existing efforts… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| SRPT-DEBT-SRPT-4-875-SENIOR-CONVERTIBLE-NOTES-DUE-SEPTEMBER-1-2030-2030-09-01 | 4.875% Senior Convertible Notes due September 1, 2030 | 94% | 4.875 % senior convertible notes due September 1, 2030. Listed in 10-Q 2026-05-06. |
| SRPT-DEBT-SRPT-1-25-SENIOR-CONVERTIBLE-NOTES-DUE-SEPTEMBER-15-2027-2027-09-15 | 1.25% Senior Convertible Notes due September 15, 2027 | 94% | 1.25 % senior convertible notes due September 15, 2027. Listed in 10-Q 2026-05-06. |
| SRPT-DEBT | Debt stack $1.0B | 90% | Market cache reports total debt of $1.0B. |
| SRPT-DEBT-12741 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| SRPT-OWNER-BLACKROCK-INC | BlackRock, Inc. | 90% | 13F overlay lists BlackRock, Inc. as top holder; 344 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| CAPR | Capricor Therapeutics, Inc. | 100.00 | 2 | ['customer', 'supplier'] |
| DYN | Dyne Therapeutics, Inc. | 100.00 | 2 | ['supplier'] |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| BCYC | Bicycle Therapeutics plc | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| WHWK | Whitehawk Therapeutics, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 100.00 | 1 | ['receiving'] |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 |